# Chronic Obstructive Pulmonary Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/chronic-obstructive-pulmonary-disease

> 6 upcoming FDA catalysts in chronic Obstructive Pulmonary Disease: verekitug (UPB) on October 2027 (primary completion); verekitug (UPB) on Oct 2027 to Jan 2028 (topline data readout); lunsekimig (SNY) on Nov 2029 to Feb 2030 (topline data readout); lunsekimig (SNY) on Nov 2029 to Feb 2030 (topline data readout); and 2 more.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| July 28, 2025 | [Fasenra (benralizumab) primary completion](https://sec-api.dev/pdufa/benralizumab) | AZN | Chronic Obstructive Pulmonary Disease | completed | "NCT04053634 (Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-28 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04053634)) |
| January 22, 2026 | [Treatment a : budesonide, glycopyrronium, and formoterol fumarate primary completion](https://sec-api.dev/pdufa/treatment-a-budesonide-glycopyrronium-and-formoterol) | AZN | Chronic Obstructive Pulmonary Disease | completed | "NCT06067828 (A Study to Evaluate the Effect of Budesonide, Glycopyrronium, Formoterol Fumarate (BGF) Metered Dose Inhaler (MDI), Budesonide and Formoterol Fumarate (BFF) MDI and Placebo MDI on Exercise Parameters in Participants With Chronic Obstructive Pulmonary Disease (COPD).): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-01-22 (ACTUAL); Lead Sponsor AstraZeneca." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06067828)) |
| September 10, 2026 | [Itepekimab (sar440340) primary completion](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Obstructive Pulmonary Disease | completed | "NCT06208306 (A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06208306)) |
| Sep to Dec 2026 | [Itepekimab (sar440340) topline data readout](https://sec-api.dev/pdufa/itepekimab-sar440340) | SNY | Chronic Obstructive Pulmonary Disease | scheduled | "NCT06208306 (A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2026-09-10 (ACTUAL); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06208306)) |
| October 2027 | [Verekitug primary completion](https://sec-api.dev/pdufa/verekitug) | UPB | Chronic Obstructive Pulmonary Disease | scheduled | "NCT06981078 (A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Upstream Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06981078)) |
| Oct 2027 to Jan 2028 | [Verekitug topline data readout](https://sec-api.dev/pdufa/verekitug) | UPB | Chronic Obstructive Pulmonary Disease | scheduled | "NCT06981078 (A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2027-10 (ESTIMATED); Lead Sponsor Upstream Bio Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06981078)) |
| Nov 2029 to Feb 2030 | [Lunsekimig topline data readout](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Obstructive Pulmonary Disease | scheduled | "NCT07190209 (Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-27 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190209)) |
| Nov 2029 to Feb 2030 | [Lunsekimig topline data readout](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Obstructive Pulmonary Disease | scheduled | "NCT07190222 (Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-27 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190222)) |
| November 2029 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Obstructive Pulmonary Disease | scheduled | "NCT07190209 (Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-27 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190209)) |
| November 2029 | [Lunsekimig primary completion](https://sec-api.dev/pdufa/lunsekimig) | SNY | Chronic Obstructive Pulmonary Disease | scheduled | "NCT07190222 (Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-11-27 (ESTIMATED); Lead Sponsor Sanofi." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07190222)) |

## Drugs

- [Fasenra (benralizumab)](https://sec-api.dev/pdufa/benralizumab) (AZN)
- [Treatment a : budesonide, glycopyrronium, and formoterol fumarate](https://sec-api.dev/pdufa/treatment-a-budesonide-glycopyrronium-and-formoterol) (AZN)
- [Itepekimab (sar440340)](https://sec-api.dev/pdufa/itepekimab-sar440340) (SNY)
- [Verekitug](https://sec-api.dev/pdufa/verekitug) (UPB)
- [Lunsekimig](https://sec-api.dev/pdufa/lunsekimig) (SNY)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/chronic-obstructive-pulmonary-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Chronic Obstructive Pulmonary Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/chronic-obstructive-pulmonary-disease

```bibtex
@misc{secapidev_indications_chronic_obstructive_pulmonary_disease_20261116,
  title        = {Chronic Obstructive Pulmonary Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/chronic-obstructive-pulmonary-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_chronic_obstructive_pulmonary_disease_20261116","title":"Chronic Obstructive Pulmonary Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/chronic-obstructive-pulmonary-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
